The COVID-19 pandemic has had a significant impact on the biopharma industry. From artificial intelligence breakthroughs to at-home genetic testing, BioSpace reviews some of the ways COVID-19 has changed the industry and what we may see in the near future.
Historically, therapies focusing on niche markets face tremendous obstacles, from drug development and clinical trials to drug access. Drew Desjardins – EVP, Chief Strategy Officer, Fishawack Health – analyzes several key challenges for brand marketers readying to launch products in these small markets, along with solutions for driving better stakeholder experiences.
With the increased number of channels available to reach healthcare professionals alongside dramatically fewer in-person opportunities due to institutional restrictions, pharma marketers are facing more challenges than ever before to break through the noise. The traditional sales pitches and mass emails are a thing of the past with the growing need to create a personalized digital strategy to reach healthcare providers.
This whitepaper covers the role that the BMC Helix portfolio can play in helping healthcare organizations to modernize their infrastructure and drive digital transformation.
Cellino Biotech announced a completed Series A financing of $80 million led by the impact investment arm of Bayer AG, Leaps by Bayer, 8VC, and Humboldt Fund and includes new investor Felicis Ventures.
Radiomics is a field of research in which image analysis is used to extract large number of quantitative features from medical images, such as MR, CT, and PET scans. While there are many potential applications of radiomics across the healthcare spectrum, oncology continues to be one of the main areas of study.
Vancouver, Wash.-based Absci Corporation inked a research pact with Merck. Absci will leverage the company’s Bionic Protein non-standard amino acid technology and its artificial intelligence-powered integrated Drug Creation Platform to create enzymes to meet Merck’s biomanufacturing applications.
French drugmaker Sanofi SA is partnering with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone payments, the two companies said on January 7.
Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.
Join this webinar to hear from regulatory affairs professionals, pharmaceutical company executives and leaders in data and AI as they discuss the challenges and opportunities for RWE across the drug lifecycle and lessons learned building successful RWE analytics programs.
